Please check your internet connection and try again.
# كلونازيبام (Clonazepam)
## Overview
A benzodiazepine with anticonvulsant, anxiolytic, and sedative-hypnotic properties. Enhances GABA-A receptor activity. High potency, intermediate onset, long duration of action (half-life 30–40 hours).
## Primary Indications
- Seizure disorders (Lennox-Gastaut syndrome, akinetic, myoclonic, and absence seizures)
- Panic disorder (with or without agoraphobia)
- Off-label: REM sleep behavior disorder, acute anxiety, status epilepticus (IV form)
## Adult Dosing
**Seizure disorders:**
- Initiate 0.5 mg orally three times daily (1.5 mg/day). May increase by 0.5–1 mg/day every 3 days.
- Usual maintenance: 4–8 mg/day in divided doses. Maximum: 20 mg/day (rarely needed).
**Panic disorder:**
- Start 0.25 mg orally twice daily. Increase to target of 1–2 mg/day (divided). Maximum: 4 mg/day.
**Status epilepticus (IV/not typical for oral):**
- 0.5–1 mg slow IV push, may repeat. Follow local protocol.
## Pediatric Dosing
**Seizures (≥10 years):**
- Initiate 0.01–0.03 mg/kg/day orally in 3 divided doses, not to exceed 0.05 mg/kg/day.
- Increase by 0.25–0.5 mg every 3 days. Usual maintenance: 0.1–0.2 mg/kg/day. Maximum: 0.2 mg/kg/day (or 20 mg/day, whichever lower).
**Panic disorder (often off-label in children):** dosing not well established; use lowest effective, consult specialist.
*Exact dosing depends on local protocol and individual response.*
## Dose Adjustments
- **Elderly or debilitated:** Start at 0.25 mg once or twice daily, increase slowly.
- **Hepatic impairment:** Reduce dose by 50–75%; contraindicated in severe hepatic disease.
- **Renal impairment:** No specific adjustment; use caution.
- **Taper when discontinuing:** Reduce by 0.125–0.25 mg every 3–7 days to avoid withdrawal seizures.
## Contraindications
- Hypersensitivity to benzodiazepines
- Severe hepatic impairment
- Narrow-angle glaucoma (untreated)
- Significant respiratory depression (e.g., sleep apnea, acute intoxication)
- Combination with opioids for cough/cold in children (FDA boxed warning)
- Pregnancy (avoid; use only if benefit outweighs risk – teratogenicity and neonatal withdrawal)
## Adverse Effects
- **Common:** Drowsiness, dizziness, ataxia, fatigue, sedation, behavioral disinhibition (especially children)
- **Serious:** Respiratory depression (especially with other CNS depressants), dependence, tolerance, withdrawal syndrome (seizures, anxiety, confusion), paradoxical reactions (anxiety, aggression)
- **Long-term:** Cognitive impairment, depression, addiction potential
## Key Drug Interactions
- **CNS depressants** (alcohol, opioids, barbiturates, Z-drugs): additive sedation and respiratory depression
- **CYP3A4 inducers** (carbamazepine, phenytoin, rifampin): decrease clonazepam levels, reduce effect
- **CYP3A4 inhibitors** (ketoconazole, erythromycin, cimetidine): increase clonazepam levels, risk of toxicity
- **Valproate:** may increase clonazepam levels (monitor)
- **Opioids (especially in combination):** avoid or dose reduce – risk of profound sedation, respiratory depression, coma, death
## Monitoring
- **Baseline:** liver function, respiratory status, suicidal ideation history, substance use history
- **Periodic:** assessment of sedation, coordination, cognitive function, signs of dependence or abuse
- **Withdrawal monitoring:** during taper – watch for anxiety, insomnia, palpitations, seizure
- **Children:** monitor for paradoxical excitation, behavioral changes
## Clinical Pearls
- **Tolerance and dependence develop rapidly** – use at lowest effective dose for shortest duration possible.
- **Do not discontinue abruptly** – taper by no more than 0.125–0.25 mg every 3–7 days; slower taper for long-term use.
- **Bioavailability:** >80% oral; available as tablets and orally disintegrating tablets (1 mg ODT ≈ 0.5 mg regular tablet in some references – confirm).
- **Abuse potential** – schedule IV controlled substance.
- **For status epilepticus,** IV lorazepam is often preferred in US; clonazepam IV used in some regions per protocol.
- **Effective for myoclonic and absence seizures** but may exacerbate tonic-clonic seizures in some patients.
- **Elderly** more sensitive to sedation and fall risk – consider alternative (e.g., low-dose SSRI for anxiety).
---
**Disclaimer:** This information is for educational purposes only and does not replace independent clinical judgment. Dosing, indications, and safety data may vary by regional guidelines and individual patient factors. Always verify current prescribing information from the manufacturer’s label and relevant institutional protocols.
